Therefore the therapeutic ratio of selective PDE4 inhibitors for use in treating asthma and chronic obstructive pulmonary disease (COPD) is defined as the PDE4H/PDE4L ratio [6,7]. The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.